Described herein is the bromodomain inhibitor 4-[2-(cyclopropylmethoxy)-5- methylsulfonylphenyl]-2-methylisoquinolin-1-one, including crystalline forms, amorphous forms, solvates, and hydrates thereof, as well as pharmaceutical compositions that include this bromodomain inhibitor. In some embodiments, the pharmaceutical composition comprises 4‑[2‑(cyclopropylmethoxy)-5- methylsulfonylphenyl]-2-methylisoquinolin-1-one that has been processed by micronization or spray dried dispersion. In some embodiments, the pharmaceutical composition further comprises at least one polymer. In some embodiments, the pharmaceutical composition comprises a solid polymer matrix comprising 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one and at least one polymer. Pharmaceutical compositions comprising 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one are useful for the treatment of cancer or neoplastic disease.茲描述溴結構域抑制劑4-[2-(環丙基甲氧基)-5-甲基磺醯基苯基]-2-甲基異喹啉-1-酮，包括上述物質的結晶形式、非晶形式、溶劑化物和水合物，及包括溴結構域抑制劑的醫藥組合物。在一些實施例中，醫藥組合物包含微粉化或噴霧乾燥分散處理的4-[2-(環丙基甲氧基)-5-甲基磺醯基苯基]-2-甲基異喹啉-1-酮。在一些實施例中，醫藥組合物進一步包含至少一種聚合物。在一些實施例中，醫藥組合物包含固體聚合物基質，固體聚合物基質包含4-[2-(環丙基甲氧基)-5-甲基磺醯基苯基]-2-甲基異喹啉-1-酮和至少一種聚合物。包含4-[2-(環丙基甲氧基)-5-甲基磺醯基苯基]-2-甲基異喹啉-1-酮的醫藥組合物可用於治療癌症或腫瘤病。
